Opendata, web and dolomites

ICone SIGNED

ICone: a novel device to scale up robotic rehabilitation and unlock the potential of motor recovery for stroke survivors.

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

Project "ICone" data sheet

The following table provides information about the project.

Coordinator
HEAXEL SRL 

Organization address
address: VIA LEOPARDI GIACOMO 7
city: MILANO
postcode: 20123
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-11-01   to  2020-02-29

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    HEAXEL SRL IT (MILANO) coordinator 50˙000.00

Map

 Project objective

ICone - The best therapy, everywhere.

THE NEED FOR REHABILITATION IS INCREASING. Increasing the effectiveness of rehabilitation and lowering its cost is a global challenge, according to WHO. Due to the ageing population and higher survival rate after brain injuries (strokes), the number of stroke patients is increasing. Even years after the cerebrovascular accident, chronic patients hold potential for motor recovery; yet, intensive, interactive, challenging and personalized therapy is needed – this requires huge cost, long time, and resources.

ROBOTIC REHABILITATION STILL FACES TECHNICAL LIMITS. Robots for rehabilitation, science confirms, could represent an adequate solution to deliver cost-effective therapy that is intensive, interactive, challenging and personalized. The main drawback is that robots for rehabilitation cannot be used outside of the hospital, and so they are precluded to chronic stroke patients.

As a result, chronic patients hold potential for motor recovery, but they don’t have access to adequate treatment (robots).

ICone: SCALE-UP OF ROBOTIC THERAPY. Heaxel produced ICone, the first portable robot for the neurorehabilitation of the upper limb, cleared for use outside of the hospital. All the ICone robots will be connected all together into a cloud network, so to facilitate the access of chronic patients to robotic therapy.

FEASIBILITY STUDY. A Phase I project will allow to carefully organize customer development activities and go-to-market strategy. The business feasibility of different revenue models must be tested, to quickly and effectively start the commercialization of the robot, in order to deliver the best possible care to chronic patients. This Phase I study will be crucial, then, for an EIC acceleration project, where pilot clinical trials will be executed, as a validation of the market and of the proposed solution. Heaxel long-term goal is to bring robotic rehabilitation directly at the patient's home.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "ICONE" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "ICONE" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Totem Spoon (2019)

Interactive Digital Signage with emotional intelligence for smart cities

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

RDNA (2019)

Empowering New Venture Growth - RDNA

Read More